Alerus Financial NA lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,431 shares of the medical instruments supplier’s stock after purchasing an additional 45 shares during the period. Alerus Financial NA’s holdings in Becton, Dickinson and were worth $3,791,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in BDX. BlackRock Inc. grew its holdings in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after purchasing an additional 796,034 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Becton, Dickinson and by 185.3% in the second quarter. Principal Financial Group Inc. now owns 909,235 shares of the medical instruments supplier’s stock valued at $177,401,000 after purchasing an additional 590,494 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Becton, Dickinson and in the first quarter valued at approximately $101,993,000. Finally, Waverton Investment Management Ltd acquired a new position in shares of Becton, Dickinson and in the second quarter valued at approximately $68,448,000. Hedge funds and other institutional investors own 87.12% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/alerus-financial-na-increases-position-in-becton-dickinson-and-company-bdx/1600224.html.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 195.95 on Friday. The stock has a market cap of $44.59 billion, a P/E ratio of 56.75 and a beta of 1.06. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The stock’s 50 day moving average is $199.01 and its 200 day moving average is $191.58.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. During the same quarter last year, the company earned $2.35 earnings per share. The business’s quarterly revenue was down 5.1% compared to the same quarter last year. Analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s payout ratio is currently 83.43%.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the sale, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock valued at $15,242,688 in the last three months. Corporate insiders own 1.40% of the company’s stock.

BDX has been the subject of several analyst reports. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen and Company reiterated an “outperform” rating and set a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Barclays PLC reiterated an “equal weight” rating and set a $210.00 price target (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a report on Monday, July 17th. Finally, Wells Fargo & Company initiated coverage on shares of Becton, Dickinson and in a report on Friday, September 22nd. They set an “outperform” rating and a $225.00 price target for the company. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and has a consensus rating of “Buy” and an average target price of $200.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.